Learn more about:

Learn more about:

the Stride dystonia clinical study > THE VISTA PD CLINICAL TRIAL >

News and publications

Stay informed about our research and other developments at Vima Therapeutics. Check back regularly for updates.

Contact us >
Reading Book
Annoucment megaphone

Press Releases

Vima Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial for Parkinson’s Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

November 5, 2026

Vima Therapeutics to Present New Research at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

October 1, 2026

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease

March 11, 2026

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

May 29, 2025
Media Player

Media

Exploring Oral Therapy with Dr. Bernard Ravina of Vima Therapeutics

Unstoppable Strides: Navigating Runner’s Dystonia
May 20, 2026

Axios Pro Premium: Venture Capital News

Axios
March 11, 2026

With $100M, Vima pursues an oral drug for movement disorders

BioPharma Dive
March 11, 2026

Emerging From Stealth With Vima Therapeutics’ Bernard Ravina, MD

Life Science Leader Podcast
November 3, 2025

Survey Highlights Key Priorities of Dystonia Patients for Better Treatments. DMRF. Dystonia Dialogue

DMRF Newsletter
October 1, 2025

Movement disorder biotech Vima steps onto scene with $60M

Endpoints News
May 29, 2025

Publications

Clinical Characteristics and Epidemiology of Isolated Dystonia: Results from a US Claims Analysis

October 8, 2026

Explore our latest science

Our research >
Vima Science